Nanjing, China

Xiaojin Yin



 

Average Co-Inventor Count = 7.0

ph-index = 2

Forward Citations = 24(Granted Patents)


Location History:

  • Jiangsu, CN (2011)
  • Nanjing, CN (2014)

Company Filing History:


Years Active: 2011-2014

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations of Xiaojin Yin in Pharmaceutical Research

Introduction

Xiaojin Yin is a notable inventor based in Nanjing, China. He has made significant contributions to the field of pharmaceutical research, particularly in the development of compositions for treating cerebrovascular diseases. With a total of 2 patents, his work showcases the intersection of chemistry and medicine.

Latest Patents

One of Xiaojin Yin's latest patents is a pharmaceutical composition that includes 3-methyl-1-phenyl-2-pyrazolin-5-one and borneol. This composition is designed for the preparation of a medicament aimed at treating cerebrovascular diseases. Another patent involves 3-pyrrolo[b]cyclohexylene-2-dihydro-indolinone derivatives, which can modulate the activity of protein kinases and inhibit various tumor cells. These innovations highlight his commitment to advancing medical treatments.

Career Highlights

Xiaojin Yin is currently associated with Jiangsu Simcere Pharmaceutical R&D Co., Ltd. His work at this company emphasizes the importance of research and development in creating effective pharmaceutical solutions. His contributions have been instrumental in the ongoing efforts to address complex health issues.

Collaborations

Xiaojin has collaborated with notable colleagues such as Feng Tang and Han Shen. These partnerships reflect the collaborative nature of research in the pharmaceutical industry, where teamwork often leads to groundbreaking discoveries.

Conclusion

Xiaojin Yin's innovative work in pharmaceutical compositions demonstrates his dedication to improving healthcare outcomes. His patents and collaborations signify a promising future in the treatment of cerebrovascular diseases and cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…